Triomics Raises $22M to Make Cancer Centers Smarter — Not Just Busier
Battery Ventures backs the oncology AI startup already embedded at Memorial Sloan Kettering and Yale Cancer Center.
Written by OutOfToken AI
June 6, 2026 · 4 min read · Synthesized from reporting by TechCrunch Startups · How this works
Cancer care is drowning in paperwork, and Triomics is placing a $22 million bet that AI can pull it back to the surface. The San Francisco-based startup has closed a Series B round led by Battery Ventures to scale its oncology-specific platform — one that automates the clinical trial matching and data entry tasks that consume thousands of physician-hours every year. It's a focused play in a crowded healthcare AI market, and the roster of early adopters suggests the approach is working.
The Problem No One Outside Oncology Talks About
Oncologists don't just treat cancer — they navigate a relentless administrative maze. Identifying eligible patients for clinical trials alone requires cross-referencing dozens of inclusion and exclusion criteria against complex medical histories, a process that is both time-critical and extraordinarily labor-intensive. Traditional EHR systems weren't designed for this level of clinical nuance, leaving nurses and coordinators to manually extract and reconcile data across platforms. Triomics targets precisely this gap, building models trained on oncology-specific language, biomarkers, and treatment pathways rather than deploying general-purpose large language models and hoping for the best.
A Platform Built for the Complexity of Cancer Data
Triomics' core product automates clinical workflow tasks including patient data extraction, structured data entry, and trial eligibility screening. The platform connects to existing hospital infrastructure, parsing unstructured clinical notes, lab results, and genomic data to surface actionable insights without requiring clinicians to overhaul their existing systems. Its adoption at institutions like Memorial Sloan Kettering Cancer Center and Yale Cancer Center signals it has cleared the high bar of enterprise healthcare procurement — environments notorious for rigorous vendor evaluation and compliance demands. The new capital will accelerate platform expansion across both workflow automation features and the breadth of cancer center partnerships.
"Triomics is already embedded at Memorial Sloan Kettering and Yale Cancer Center — two of the most demanding proving grounds in American oncology."
Why Battery Ventures Is Writing the Check
Battery Ventures has built a deliberate track record in enterprise software and healthcare technology, and Triomics fits the firm's preference for companies solving high-friction, data-dense operational problems with defensible domain expertise. Oncology AI is increasingly competitive — players from large health systems to well-funded startups are all vying for position — but Triomics' specialization creates a meaningful moat. Vertical AI built on proprietary clinical data and refined through real-world deployment at top cancer centers is difficult to replicate with horizontal foundation models. Existing investors also participated in the round, reinforcing confidence in the company's trajectory since its earlier raises.
As healthcare systems face mounting pressure to do more with constrained clinical resources, the appetite for tools that genuinely reduce cognitive and administrative load — rather than simply digitizing old inefficiencies — will only intensify. Triomics is positioning itself as the infrastructure layer for oncology operations, and with $22 million in fresh capital and blue-chip cancer centers already on its client list, it has both the credibility and the runway to define what oncology AI looks like at scale. The real test will be whether it can expand without losing the precision that made it worth betting on in the first place.
Editorial Note
TechCrunch is a reputable technology news source with established credibility for covering startup funding rounds. The claim is specific and plausible (oncology AI is an active investment area), though without access to real-time databases, direct verification of this particular round's existence and exact terms cannot be confirmed. Battery Ventures is a legitimate venture capital firm known for life sciences investments, making their involvement credible.
Claim Tracker
AI-assessed
Specific, checkable funding claim
Accurate description of standard oncology practice
Well-established limitation of general-purpose EHR systems
Technical capability claim not independently substantiated; no details on training data or model validation
Quantitative claim lacking source; appears estimated/approximate
Ask AI about this story
// discussion
sign in to join the discussion